Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

94 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Austrian recommendations for the management of essential thrombocythemia.
Buxhofer-Ausch V, Heibl S, Sliwa T, Beham-Schmid C, Wolf D, Geissler K, Krauth MT, Krippl P, Petzer A, Wölfler A, Melchardt T, Gisslinger H. Buxhofer-Ausch V, et al. Among authors: melchardt t. Wien Klin Wochenschr. 2021 Jan;133(1-2):52-61. doi: 10.1007/s00508-020-01761-3. Epub 2020 Nov 19. Wien Klin Wochenschr. 2021. PMID: 33215234
How I treat diffuse large B-cell lymphoma.
Melchardt T, Egle A, Greil R. Melchardt T, et al. ESMO Open. 2023 Feb;8(1):100750. doi: 10.1016/j.esmoop.2022.100750. Epub 2023 Jan 10. ESMO Open. 2023. PMID: 36634531 Free PMC article. Review.
Azacitidine in patients with WHO-defined AML - results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group.
Pleyer L, Stauder R, Burgstaller S, Schreder M, Tinchon C, Pfeilstocker M, Steinkirchner S, Melchardt T, Mitrovic M, Girschikofsky M, Lang A, Krippl P, Sliwa T, Egle A, Linkesch W, Voskova D, Angermann H, Greil R. Pleyer L, et al. Among authors: melchardt t. J Hematol Oncol. 2013 Apr 29;6:32. doi: 10.1186/1756-8722-6-32. J Hematol Oncol. 2013. PMID: 23627920 Free PMC article. Clinical Trial.
Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b.
Them NC, Bagienski K, Berg T, Gisslinger B, Schalling M, Chen D, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, Wolf D, Strecker K, Egle A, Melchardt T, Burgstaller S, Willenbacher E, Zagrijtschuk O, Klade C, Greil R, Gisslinger H, Kralovics R. Them NC, et al. Among authors: melchardt t. Am J Hematol. 2015 Apr;90(4):288-94. doi: 10.1002/ajh.23928. Epub 2015 Mar 2. Am J Hematol. 2015. PMID: 25545244 Free PMC article. Clinical Trial.
The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients.
Troppan KT, Melchardt T, Deutsch A, Schlick K, Stojakovic T, Bullock MD, Reitz D, Beham-Schmid C, Weiss L, Neureiter D, Wenzl K, Greil R, Neumeister P, Egle A, Pichler M. Troppan KT, et al. Among authors: melchardt t. Eur J Haematol. 2015 Dec;95(6):538-44. doi: 10.1111/ejh.12529. Epub 2015 Mar 26. Eur J Haematol. 2015. PMID: 25677782
Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera.
Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, Wolf D, Kralovics R, Gisslinger B, Strecker K, Egle A, Melchardt T, Burgstaller S, Willenbacher E, Schalling M, Them NC, Kadlecova P, Klade C, Greil R. Gisslinger H, et al. Among authors: melchardt t. Blood. 2015 Oct 8;126(15):1762-9. doi: 10.1182/blood-2015-04-637280. Epub 2015 Aug 10. Blood. 2015. PMID: 26261238 Free PMC article. Clinical Trial.
NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients.
Prochazka KT, Melchardt T, Posch F, Schlick K, Deutsch A, Beham-Schmid C, Weiss L, Gary T, Neureiter D, Klieser E, Greil R, Neumeister P, Egle A, Pichler M. Prochazka KT, et al. Among authors: melchardt t. Br J Cancer. 2016 Nov 8;115(10):1264-1272. doi: 10.1038/bjc.2016.325. Epub 2016 Oct 20. Br J Cancer. 2016. PMID: 27764838 Free PMC article.
Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.
Egle A, Steurer M, Melchardt T, Weiss L, Gassner FJ, Zaborsky N, Geisberger R, Catakovic K, Hartmann TN, Pleyer L, Voskova D, Thaler J, Lang A, Girschikofsky M, Petzer A, Greil R. Egle A, et al. Among authors: melchardt t. Ann Hematol. 2018 Oct;97(10):1825-1839. doi: 10.1007/s00277-018-3380-z. Epub 2018 Jun 4. Ann Hematol. 2018. PMID: 29862437 Free PMC article. Clinical Trial.
Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.
Egle A, Steurer M, Melchardt T, Weiss L, Gassner FJ, Zaborsky N, Geisberger R, Catakovic K, Hartmann TN, Pleyer L, Voskova D, Thaler J, Lang A, Girschikofsky M, Petzer A, Greil R. Egle A, et al. Among authors: melchardt t. Ann Hematol. 2018 Sep;97(9):1745. doi: 10.1007/s00277-018-3403-9. Ann Hematol. 2018. PMID: 29934835 Free PMC article.
94 results